On December 31, 2020, Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) closed a non-brokered private placement offering of units for aggregate gross proceeds of $2,367,804.

Innocan is an Israeli pharmaceutical technology company that focuses on the development of several drug delivery platforms combining cannabidiol ("CBD") with other pharmaceutical ingredients.

Gowling WLG advised Innocan with respect to this private placement with a team that included Jason A. Saltzman, Joseph McDonald and Quinn Clement-Schlimm.